BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 33706868)

  • 41. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
    Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
    JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
    Alfredsson J; Neely B; Neely ML; Bhatt DL; Goodman SG; Tricoci P; Mahaffey KW; Cornel JH; White HD; Fox KA; Prabhakaran D; Winters KJ; Armstrong PW; Ohman EM; Roe MT;
    Heart; 2017 Aug; 103(15):1168-1176. PubMed ID: 28381584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting.
    Holm M; Biancari F; Khodabandeh S; Gherli R; Airaksinen J; Mariscalco G; Gatti G; Reichart D; Onorati F; De Feo M; Santarpino G; Rubino AS; Maselli D; Santini F; Nicolini F; Zanobini M; Kinnunen EM; Ruggieri VG; Perrotti A; Rosato S; Dalén M
    Ann Thorac Surg; 2019 Jun; 107(6):1690-1698. PubMed ID: 30898561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
    Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
    Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
    Pourdjabbar A; Hibbert B; Chong AY; Le May MR; Labinaz M; Simard T; Ramirez FD; Lugomirski P; Maze R; Froeschl M; Glover C; Dick A; Marquis JF; Bernick J; Wells G; So DY;
    Thromb Haemost; 2017 Jan; 117(2):303-310. PubMed ID: 27761582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis.
    Cao C; Indraratna P; Ang SC; Manganas C; Park J; Bannon PG; Yan TD
    J Thorac Cardiovasc Surg; 2014 Dec; 148(6):3092-8. PubMed ID: 24954178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of platelet reactivity assessment in dual antiplatelet prophylaxis after transcatheter aortic valve implantation.
    Czerwińska-Jelonkiewicz K; Witkowski A; Dąbrowski M; Piotrowski W; Hryniewiecki T; Stępińska J
    Arch Cardiovasc Dis; 2018 Apr; 111(4):233-245. PubMed ID: 29126843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pretreatment with a P2Y12 receptor inhibitor and delay to coronary artery bypass surgery in patients with non-ST segment elevation acute coronary syndrome.
    Gomes DA; Rocha BM; Ferreira J; Paiva MS; Reis Santos R; Santos MR; Cunha G; DE Araújo Gonçalves P; Fevereiro S; Trabulo M; Aguiar C; Sousa-Uva M; Neves J; Mendes M
    Minerva Cardiol Angiol; 2023 Oct; 71(5):582-589. PubMed ID: 36475547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin.
    Ouattara A; Bouzguenda H; Le Manach Y; Léger P; Mercadier A; Leprince P; Bonnet N; Montalescot G; Riou B; Coriat P
    Eur Heart J; 2007 Apr; 28(8):1025-32. PubMed ID: 17431000
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
    Xue HJ; Shi J; Liu B; Wang DY; Dong ZX; Guo H; Kong YH; Sheng L; Shao Q; Sun DH; Zhang L; Pan YJ; Dong XW; Li JQ; Xue JY; Zhou YY; Yang HP; Li Y
    Platelets; 2016 Jul; 27(5):440-5. PubMed ID: 26830862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization.
    Marquis-Gravel G; Neely ML; Valgimigli M; Costa F; Van Klaveren D; Altner R; Bhatt DL; Armstrong PW; Fox KAA; White HD; Ohman EM; Roe MT
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006582. PubMed ID: 32862694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
    Berger JS; Frye CB; Harshaw Q; Edwards FH; Steinhubl SR; Becker RC
    J Am Coll Cardiol; 2008 Nov; 52(21):1693-701. PubMed ID: 19007688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.
    Tantry US; Bonello L; Aradi D; Price MJ; Jeong YH; Angiolillo DJ; Stone GW; Curzen N; Geisler T; Ten Berg J; Kirtane A; Siller-Matula J; Mahla E; Becker RC; Bhatt DL; Waksman R; Rao SV; Alexopoulos D; Marcucci R; Reny JL; Trenk D; Sibbing D; Gurbel PA;
    J Am Coll Cardiol; 2013 Dec; 62(24):2261-73. PubMed ID: 24076493
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.